retatrutide trial news Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Retatrutide Meets Phase 3 Weight-Loss

2023;8(3): e10505

A special thanks to the head of the metabolic kitchen at my old department (now Department of Nutrition, Exercise and Sports), Charlotte Kostecki, for her invaluable creativity and support, and to my former PA Tina Cuthbertson for making it possible to be head of the department and still conducting research

Most AEs were mild in severity, and a higher proportion of participants reported an AE following administration of PF-06882961 at the 300 mg dose level, compared with other study treatments (Table S10)

& Magdy, Y

NICE can begin its appraisal process before a licence is granted, meaning the two stages may overlap